title: Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
abstract: We evaluated long-term outcomes of 60 patients with chronic lymphocytic leukemia treated with an initial therapy of lenalidomide. At a median follow-up of 4 years, time-to-treatment failure has not been reached and overall survival is 82%. Thirty-five (58%) patients had a response lasting >36 months (long-term responders [LTRs]). Best LTR responses consisted of 25 (71%) complete remissions and 10 (29%) partial remissions. In addition to clinical responses, an increase in IgA, IgG, and IgM levels of >50% from baseline was reported in 61%, 45%, and 42% of LTRs. Normalization in the percentage of CD4+ and CD8+ cells and T-cell numbers was observed in 48%, 71% and 99% of LTRs. Compared with other patients in the study, LTRs had lower baseline plasma levels of β-2-microglobulin, were more likely to have trisomy 12, and less likely to have deletion 17p.
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Paolo
authors.initials: P
authors.lastname: Strati
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Xavier C
authors.initials: XC
authors.lastname: Badoux
authors.forename: Steliana
authors.initials: S
authors.lastname: Calin
authors.forename: James M
authors.initials: JM
authors.lastname: Reuben
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Steven M
authors.initials: SM
authors.lastname: Kornblau
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Hui
authors.initials: H
authors.lastname: Gao
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D018365:Neoplasm, Residual; D012074:Remission Induction; D013601:T-Lymphocytes / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide